Skip to main content
. Author manuscript; available in PMC: 2013 Dec 13.
Published in final edited form as: J Med Chem. 2012 Nov 8;55(22):10.1021/jm301002f. doi: 10.1021/jm301002f

Figure 1.

Figure 1

Screening of A) X-Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-MALP-2 derived peptide library (compounds 1-7) and B) compound analogs (8-10) with an Ac-PEGO-Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-Y and SAA for TLR2 agonist activity determined using the functional bioassay. All compounds exhibit high luminescence intensities similar to the TLR2 agonist controls, Pam2CSK4 and Pam3CSK4, using the HEK-293/hTLR2 cells (n = 3 assays with quadruplicate wells, p value<0.0003). Dose-response curves generated by measuring the TLR2 agonistic activity for C) compound 10 and D) compound 13. Performed by serially adding (0.001 ng/mL to 10 μg/mL) compound to HEK-293/hTLR2 expressing cells (n > 3 assays with quadruplicate wells, R2 > 0.98).